Handelsbanken Fonder Ab Dyne Therapeutics, Inc. Call Options Transaction History
Handelsbanken Fonder Ab
- $25.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DYN
# of Institutions
209Shares Held
102MCall Options Held
234KPut Options Held
238K-
Atlas Venture Life Science Advisors, LLC8.02MShares$196 Million35.54% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$181 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.86MShares$168 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.82MShares$167 Million3.9% of portfolio
-
Janus Henderson Group PLC London, X06.81MShares$167 Million0.13% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.27B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...